Annual Operating Expenses
$59.10 M
-$1.60 M-2.64%
December 31, 2022
Summary
- As of February 10, 2025, NLTX annual total operating expenses is $59.10 million, with the most recent change of -$1.60 million (-2.64%) on December 31, 2022.
- During the last 3 years, NLTX annual operating expenses has risen by +$35.85 million (+154.26%).
Performance
NLTX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Operating Expenses
$5.57 M
+$2.50 M+81.64%
September 30, 2023
Summary
- As of February 10, 2025, NLTX quarterly total operating expenses is $5.57 million, with the most recent change of +$2.50 million (+81.64%) on September 30, 2023.
- Over the past year, NLTX quarterly operating expenses has dropped by -$8.04 million (-59.08%).
Performance
NLTX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
NLTX Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -2.6% | -59.1% |
| 3 y3 years | +154.3% | -44.7% |
| 5 y5 years | +15.6% | -63.4% |
NLTX Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -2.6% | at low | -64.9% | -44.9% |
| 5 y | 5-year | -2.6% | -60.7% | -64.9% | -44.9% |
| alltime | all time | -2.6% | -87.0% | -75.0% | -92.3% |
Neoleukin Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $5.57 M(+81.6%) |
| Jun 2023 | - | $3.07 M(-73.8%) |
| Mar 2023 | - | $11.72 M(-17.8%) |
| Dec 2022 | $59.10 M(-2.6%) | $14.25 M(+4.7%) |
| Sep 2022 | - | $13.61 M(-14.3%) |
| Jun 2022 | - | $15.87 M(+3.3%) |
| Mar 2022 | - | $15.37 M(+1.3%) |
| Dec 2021 | $60.70 M(+46.1%) | $15.17 M(-1.8%) |
| Sep 2021 | - | $15.45 M(+2.2%) |
| Jun 2021 | - | $15.12 M(+1.2%) |
| Mar 2021 | - | $14.95 M(+18.3%) |
| Dec 2020 | $41.55 M(+78.8%) | $12.64 M(+25.4%) |
| Sep 2020 | - | $10.08 M(+3.1%) |
| Jun 2020 | - | $9.77 M(+7.7%) |
| Mar 2020 | - | $9.07 M(+8.6%) |
| Dec 2019 | $23.24 M(-59.7%) | $8.36 M(-29.2%) |
| Sep 2019 | - | $11.80 M(+2657.0%) |
| Jun 2019 | - | $428.00 K(-83.9%) |
| Mar 2019 | - | $2.66 M(-49.8%) |
| Dec 2018 | $57.62 M | $5.30 M(-65.1%) |
| Sep 2018 | - | $15.20 M(-31.9%) |
| Jun 2018 | - | $22.31 M(+50.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $14.82 M(-10.4%) |
| Dec 2017 | $51.12 M(+35.8%) | $16.53 M(+37.0%) |
| Sep 2017 | - | $12.07 M(-13.8%) |
| Jun 2017 | - | $13.99 M(+64.2%) |
| Mar 2017 | - | $8.52 M(-25.7%) |
| Dec 2016 | $37.65 M(+76.4%) | $11.46 M(+38.4%) |
| Sep 2016 | - | $8.28 M(-25.1%) |
| Jun 2016 | - | $11.06 M(+61.9%) |
| Mar 2016 | - | $6.83 M(+22.2%) |
| Dec 2015 | $21.34 M(-4.6%) | $5.59 M(+13.7%) |
| Sep 2015 | - | $4.92 M(+2.6%) |
| Jun 2015 | - | $4.79 M(-20.6%) |
| Mar 2015 | - | $6.04 M(-22.8%) |
| Dec 2014 | $22.38 M(+138.6%) | $7.82 M(+23.9%) |
| Sep 2014 | - | $6.31 M(+12.0%) |
| Jun 2014 | - | $5.63 M(+115.4%) |
| Mar 2014 | - | $2.62 M(-24.1%) |
| Dec 2013 | $9.38 M(+22.1%) | $3.44 M(+0.8%) |
| Sep 2013 | - | $3.42 M(+111.3%) |
| Jun 2013 | - | $1.62 M(+62.2%) |
| Mar 2013 | - | $996.80 K |
| Dec 2012 | $7.68 M | - |
FAQ
- What is Neoleukin Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual operating expenses year-on-year change?
- What is Neoleukin Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly operating expenses year-on-year change?
What is Neoleukin Therapeutics annual total operating expenses?
The current annual operating expenses of NLTX is $59.10 M
What is the all time high annual operating expenses for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual total operating expenses is $60.70 M
What is Neoleukin Therapeutics annual operating expenses year-on-year change?
Over the past year, NLTX annual total operating expenses has changed by -$1.60 M (-2.64%)
What is Neoleukin Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of NLTX is $5.57 M
What is the all time high quarterly operating expenses for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly total operating expenses is $22.31 M
What is Neoleukin Therapeutics quarterly operating expenses year-on-year change?
Over the past year, NLTX quarterly total operating expenses has changed by -$8.04 M (-59.08%)